26 Beaumont Street
About Oxford BiodynamicsOBD was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases.
CEO: Christian Hoyer Millar
CSO: Alexandre Akoulitchev
CTO: Aroul Ramadass
CFO: Katie Long
15 articles about Oxford Biodynamics
Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men
Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch ® 3D genomics platform, announced that its senior leadership will be in San Francisco during the 41st Annual J.P. Morgan Healthcare Conference, Jan 9-12 2023.
Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS
Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces the initial results from an interim analysis conducted for the REFINE-ALS prospective trial.
Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.
Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies
Oxford BioDynamics announces that it has been awarded an FNIH Partnership for Accelerating Cancer Therapies (PACT) Grant to use the EpiSwitch diagnostic platform for accurate prediction of a patient’s response to Immune Checkpoint Inhibitors (ICIs) from a routine blood sample.
The Prime Meridian Group is providing Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry, assistance with market research related to the testing for the award-winning, proprietary technology platform, EpiSwitch™.
Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use
Launch of the EpiSwitch® Explorer Array Kit expands academic and clinical researcher access to OBD’s EpiSwitch® technology platform following the launch of its EpiSwitch®CST (COVID-19 Severity Test)
EpiSwitch® CST is a highly accurate prognostic test that predicts personalized risk of severe illness due to SARS-CoV-2 virus
Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19
Highly diverse samples will enable development of world’s first 3D genomics prognostic immune health test for disease severity
10/29/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Oxford BioDynamics Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University
Expertly annotated patient samples from world-class clinical research facility Samples used to advance development of the world’s first 3D genomic severity test for COVID-19 disease built using the EpiSwitch™ platform Goal is to provide insight into a wide range of COVID-19 responses, from mild to severe Adds to Oxford BioDynamics’ growing bank of 500+ procured samples from cohorts around the world
Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, today announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at The Society for Immunotherapy of Cancer's 34th Annual Meeting.
Proprietary Technology Platform to Assess Biomarker Panels in People with ALS
Oxford Biodynamics Presents Applications Of Its Epigenetic Biomarker Technology EpiSwitch At The Annual Meeting Of The American Society of Hematology In San Diego